- Home
- INCY vs ICLR Comparison
INCY vs ICLR Comparison
Compare INCY & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- ICLR
- Stock Information
- Founded
- INCY 1991
- ICLR 1990
- Country
- INCY United States
- ICLR Ireland
- Employees
- INCY N/A
- ICLR N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- Sector
- INCY Health Care
- ICLR Health Care
- Exchange
- INCY Nasdaq
- ICLR Nasdaq
- Market Cap
- INCY 13.4B
- ICLR 11.4B
- IPO Year
- INCY 1993
- ICLR 1998
- Fundamental
- Price
- INCY $65.06
- ICLR $130.28
- Analyst Decision
- INCY Hold
- ICLR Buy
- Analyst Count
- INCY 19
- ICLR 12
- Target Price
- INCY $72.67
- ICLR $204.18
- AVG Volume (30 Days)
- INCY 1.8M
- ICLR 1.6M
- Earning Date
- INCY 04-29-2025
- ICLR 07-23-2025
- Dividend Yield
- INCY N/A
- ICLR N/A
- EPS Growth
- INCY N/A
- ICLR 11.53
- EPS
- INCY 0.10
- ICLR 9.19
- Revenue
- INCY $4,413,226,000.00
- ICLR $8,192,621,999.00
- Revenue This Year
- INCY $13.29
- ICLR N/A
- Revenue Next Year
- INCY $10.43
- ICLR $2.34
- P/E Ratio
- INCY $592.09
- ICLR $14.18
- Revenue Growth
- INCY 17.13
- ICLR N/A
- 52 Week Low
- INCY $53.56
- ICLR $125.10
- 52 Week High
- INCY $83.95
- ICLR $347.72
- Technical
- Relative Strength Index (RSI)
- INCY 60.01
- ICLR 39.23
- Support Level
- INCY $63.51
- ICLR $125.10
- Resistance Level
- INCY $66.26
- ICLR $132.96
- Average True Range (ATR)
- INCY 1.60
- ICLR 4.34
- MACD
- INCY 0.32
- ICLR 0.79
- Stochastic Oscillator
- INCY 83.12
- ICLR 29.63
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.